Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer

被引：0
|
作者：
Jang, T. W. [1 ]
Kim, T. [2 ]
机构：
[1] Kosin Univ Gospel Hosp, Busan, South Korea
[2] Armed Forces Goyang Hosp, Goyang, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Afatinib; osimertinib; real-world effectiveness;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-27
引用
收藏
页码：S651 / S651
页数：1
相关论文
共 50 条
  • [41] Real-World Data on Osimertinib in Chinese Patients with Pretreated, EGFR T790M Mutation Positive, Advanced Non-Small Cell Lung Cancer: A Retrospective Study
    Peng, Da
    Shan, Dongfeng
    Dai, Chengcheng
    Li, Jie
    Wang, Zifan
    Huang, Ziyi
    Peng, Rui
    Zhao, Peng
    Ma, Xuezhen
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 2033 - 2039
  • [42] Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
    Mu, Yuxin
    Xing, Puyuan
    Hao, Xuezhi
    Wang, Yan
    Li, Junling
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9243 - 9251
  • [43] A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation
    Craig, Daniel J.
    Kahlon, Navkirat K.
    Hamouda, Danae M.
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 8
  • [44] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Cam Phuong Pham
    Thi Thai Hoa Nguyen
    Anh Tu Do
    Tuan Khoi Nguyen
    Thi Anh Thu Hoang
    Tuan Anh Le
    Dinh Thy Hao Vuong
    Dac Nhan Tam Nguyen
    Van Khiem Dang
    Thi Oanh Nguyen
    Van Luan Pham
    Minh Hai Nguyen
    Thi Huyen Trang Vo
    Hung Kien Do
    Ha Thanh Vu
    Thi Thuy Hang Nguyen
    Van Thai Pham
    Le Huy Trinh
    Khac Dung Nguyen
    Hoang Gia Nguyen
    Cong Minh Truong
    Tran Minh Chau Pham
    Thi Bich Phuong Nguyen
    BMC Cancer, 24
  • [45] A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam
    Pham, P. C.
    Nguyen, H. T. T.
    Do, T. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S668 - S669
  • [46] Overcoming Osimertinib Resistance in Advanced Non-small Cell Lung Cancer
    Lim, J. U.
    CLINICAL ONCOLOGY, 2021, 33 (10) : 619 - 626
  • [47] Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
    René J. Boosman
    Merel Jebbink
    Wouter B. Veldhuis
    Stefanie L. Groenland
    Bianca A. M. H. van Veggel
    Pim Moeskops
    Adrianus J. de Langen
    Jos H. Beijnen
    Egbert F. Smit
    Alwin D. R. Huitema
    Neeltje Steeghs
    Pharmaceutical Research, 2022, 39 : 2507 - 2514
  • [48] CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
    Kang, Liping
    Mai, Jianliang
    Liang, Weiting
    Zou, Qihua
    Huang, Caiwen
    Lin, Yongbin
    Liang, Ying
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [49] Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer
    Tian, Wentao
    Niu, Lishui
    Zhou, Rongrong
    Wang, Ziqi
    Ning, Jiaoyang
    Lu, Ruoyu
    Shi, Yin
    Tan, Zhaohua
    CANCER MEDICINE, 2024, 13 (16):
  • [50] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
    Pham, Cam Phuong
    Nguyen, Thi Thai Hoa
    Do, Anh Tu
    Nguyen, Tuan Khoi
    Hoang, Thi Anh Thu
    Le, Tuan Anh
    Vuong, Dinh Thy Hao
    Nguyen, Dac Nhan Tam
    Dang, Van Khiem
    Nguyen, Thi Oanh
    Pham, Van Luan
    Nguyen, Minh Hai
    Vo, Thi Huyen Trang
    Do, Hung Kien
    Vu, Ha Thanh
    Nguyen, Thi Thuy Hang
    Pham, Van Thai
    Trinh, Le Huy
    Nguyen, Khac Dung
    Nguyen, Hoang Gia
    Truong, Cong Minh
    Pham, Tran Minh Chau
    Nguyen, Thi Bich Phuong
    BMC CANCER, 2024, 24 (01)
12345